Editing Mode Sensors

{{DISPLAYTITLE:Mode Sensors}}
{{Infobox company
| name = Mode Sensors AS
| org_number = 816650402
| founded = 2016-01-22
| employees = 10
| address = Norway
| industry = 72.100 – Biotechnology research
| website = https://www.modesensors.com
| nht_category = Startup
| description = Mode Sensors develops Re:Balans, an FDA-cleared medical-grade wearable for non-invasive real-time fluid monitoring. The device addresses fluid management — a critical clinical challenge in heart failure, kidney disease, and general hospital monitoring. The company also has a US market focus.
| notes = 10 employees. FDA clearance is a significant regulatory milestone. Fluid monitoring for heart failure is a large market with high unmet need.
| related_companies = [[Invivo Bionics]], [[GlucoSet]], [[Cardiaccs]], [[Norway Health Tech]]
| categories = Norway Health Tech, Startups, Wearables, Medical Devices, Cardiovascular, Remote Monitoring
| sources = https://www.modesensors.com; https://data.brreg.no/enhetsregisteret/api/enheter/816650402
}}

== About ==

Mode Sensors AS is a Norwegian medical technology company developing wearable monitoring solutions for fluid management in clinical settings. Founded in 2016 with 10 employees.

== Product ==

=== Re:Balans ===

Re:Balans is an FDA-cleared medical-grade wearable device for non-invasive, real-time fluid monitoring. Key features:

* Non-invasive measurement of fluid status
* Real-time monitoring capability
* Medical-grade accuracy
* US market clearance (FDA)

== Clinical Need ==

Fluid overload (hypervolemia) and dehydration (hypovolemia) are common clinical challenges in:
* Heart failure patients
* Kidney disease patients
* Post-operative patients
* General hospital ward monitoring

Current methods for assessing fluid status (weight, physical exam, invasive central venous pressure) are imprecise or risky. A non-invasive wearable that continuously monitors fluid status addresses a significant clinical gap.

== Market Position ==

FDA clearance is a significant achievement and regulatory milestone. The US market focus indicates commercial ambition beyond Norway. Heart failure affects approximately 64 million people globally, representing a large addressable market.

== References ==
<references/>

[[Category:Norway Health Tech]]
[[Category:Startups]]
[[Category:Wearables]]
[[Category:Medical Devices]]
[[Category:Cardiovascular]]
[[Category:Remote Monitoring]]